Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1

Virologica Sinica

Volumn 28, Issue 2, 2013, Pages 71-80

  Zhu, Zhongyu ^a   Prabakaran, Ponraj ^a,b   Chen, Weizao ^a   Broder, Christopher C ^c   Gong, Rui ^d   Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Antibodies; Hendra virus; Nipah virus; SARS CoV; Viruses

Indexed keywords

BISPECIFIC ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY;

ABSENCE OF SIDE EFFECTS; CLINICAL EFFECTIVENESS; DISEASE ASSOCIATION; DRUG DESIGN; DRUG DETERMINATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG ISOLATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; EBOLA HEMORRHAGIC FEVER; EBOLA VIRUS; FOOD AND DRUG ADMINISTRATION; HENDRA VIRUS; HENDRA VIRUS INFECTION; HIGH THROUGHPUT SEQUENCING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS; MOLECULAR DYNAMICS; NIPAH VIRUS; NIPAH VIRUS INFECTION; NONHUMAN; OUTCOME ASSESSMENT; REVIEW; SARS CORONAVIRUS; SEQUENCE ANALYSIS; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS NEUTRALIZATION; WEST NILE FEVER; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, MONOCLONAL; HENDRA VIRUS; HIV-1; HUMANS; NIPAH VIRUS; SARS VIRUS; VIRUS DISEASES;

EID: 84879728492     PISSN: 16740769     EISSN: 1995820X     Source Type: Journal    
DOI: 10.1007/s12250-013-3313-x     Document Type: Review

References (104)

1. Ashkenazi A. 2008. Directing cancer cells to self-destruct with pro-apoptotic receptor agonists. Nature Reviews Drug Discovery, 7:1001-1012.
2. Bale S, Dias J M, Fusco M L, Hashiguchi T, Wong A C, Liu T, Keuhne A I, Li S, Woods V L, Jr., Chandran K, Dye J M, and Saphire E O. 2012. Structural basis for differential neutralization of ebolaviruses. Viruses, 4:447-470.
3. Bonsignori M, Alam S M, Liao H X, Verkoczy L, Tomaras G D, Haynes B F, and Moody M A. 2012. HIV-1 antibodies from infection and vaccination: insights for guiding vaccine design. Trends Microbiol, 20:532-539.
4. Bossart K N, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern J A, Green D, Hancock T J, Chan Y P, Hickey A C, Dimitrov D S, Wang L F, and Broder C C. 2009. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection. PLoS Pathog, 5:e1000642.
5. Bossart K N, Geisbert T W, Feldmann H, Zhu Z, Feldmann F, Geisbert J B, Yan L, Feng Y R, Brining D, Scott D, Wang Y, Dimitrov A S, Callison J, Chan Y P, Hickey A C, Dimitrov D S, Broder C C, and Rockx B. 2011. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. Sci Transl Med, 3:105ral03.
6. Bouchet J, Basmaciogullari S E, Chrobak P, Stolp B, Bouchard N, Fackler O T, Chames P, Jolicoeur P, Benichou S, and Baty D. 2011. Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood, 117:3559-3568.
7. Bowden T A, Aricescu A R, Gilbert R J, Grimes J M, Jones E Y, and Stuart D I. 2008. Structural basis of Nipah and Hendra virus attachment to their cell-surface receptor ephrin-B2. Nat Struct Mol Biol, 15:567-572.
8. Bugli F, Manzara S, Torelli R, Graffeo R, Santangelo R, Cattani P, and Fadda G. 2004. Human monoclonal antibody fragment specific for glycoprotein G in herpes simplex virus type 2 with applications for serotype-specific diagnosis. J Clin Microbiol, 42:1250-1253.
9. Burton D R, Pyati J, Koduri R, Sharp S J, Thornton G B, Parren P W, Sawyer L S, Hendry R M, Dunlop N, Nara P L, and et al. 1994. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science, 266:1024-1027.
10. Carter P J. 2006. Potent antibody therapeutics by design. Nature Reviews Immunology, 6:343-357.
11. Casadevall A, Dadachova E, and Pirofski L. 2004. Passive antibody therapy for infectious diseases. Nature Reviews Microbiology, 2:695-703.
12. Chen L, Kwon Y D, Zhou T, Wu X, O'Dell S, Cavacini L, Hessell A J, Pancera M, Tang M, Xu L, Yang Z Y, Zhang M Y, Arthos J, Burton D R, Dimitrov D S, Nabel G J, Posner M R, Sodroski J, Wyatt R, Mascola J R, and Kwong P D. 2009. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gpl20. Science, 326:1123-1127.
13. Chen W, Zhu Z, Feng Y, and Dimitrov D S. 2008. Human domain antibodies to conserved sterically restricted regions on gpl20 as exceptionally potent cross-reactive HIV-1 neutralizes. Proc Natl Acad Sci USA, 105:17121-17126.
14. Chen W, Prabakaran P, Zhu Z, Feng Y, Streaker E D, and Dimitrov D S. 2012. Characterization of human IgG repertoires in an acute HIV-1 infection. Exp Mol Pathol, 93:399-407.
15. Chen W, Streaker E D, Russ D E, Feng Y, Prabakaran P, and Dimitrov D S. 2012. Characterization of germline antibody libraries from human umbilical cord blood and selection of monoclonal antibodies to viral envelope glycoproteins: Implications for mechanisms of immune evasion and design of vaccine immunogens. Biochem Biophys Res Commun, 417:1164-1169.
16. Chen W, Zhu Z, Liao H, Quinnan G V, Jr., Broder C C, Haynes B F, and Dimitrov D S. 2010. Cross-Reactive Human IgM-Derived Monoclonal Antibodies that Bind to HIV-1 Envelope Glycoproteins. Viruses, 2:547-565.
17. Corti D, Suguitan A L, Jr., Pinna D, Silacci C, Fernandez-Rodriguez B M, Vanzetta F, Santos C, Luke C J, Torres-Velez F J, Temperton N J, Weiss R A, Sallusto F, Subbarao K, and Lanzavecchia A. 2010. Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest, 120:1663-1673.
18. Corti D, Voss J, Gamblin S J, Codoni G, Macagno A, Jarrossay D, Vachieri S G, Pinna D, Minola A, Vanzetta F, Silacci C, Fernandez-Rodriguez B M, Agatic G, Bianchi S, Giacchetto-Sasselli I, Calder L, Sallusto F, Collins P, Haire L F, Temperton N, Langedijk J P, Skehel J J, and Lanzavecchia A. 2011. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science, 333:850-8S6.
19. Coughlin M M, and Prabhakar B S. 2012. Neutralizing human monoclonal antibodies to severe acute respiratory syndrome coronavirus: target, mechanism of action, and therapeutic potential. Rev Med Virol, 22:2-17.
20. Darbha R, Phogat S, Labrijn A F, Shu Y, Gu Y, Andrykovitch M, Zhang M Y, Pantophlet R, Martin L, Vita C, Burton D R, Dimitrov D S, and Ji X. 2004. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab XS and fine mapping of its epitope. Biochemistry, 43:1410-1417.
21. Deschacht N, De Groeve K, Vincke C, Raes G, De Baetselier P, and Muyldermans S. 2010. A novel promiscuous class of camelid single-domain antibody contributes to the antigen-binding repertoire. J Immunol, 184:5696-5704.
22. Dimitrov D S. 2009. Engineered CH2 domains (nanoantibodies). Mabs, 1:26-28.
23. Dimitrov D S. 2010. Therapeutic antibodies, vaccines and antibodyomes. Mabs, 2:347-356.
24. Dimitrov D S. 2012. Therapeutic proteins. Methods Mol Biol, 899:1-26.
25. Dreyfus C, Laursen N S, Kwaks T, Zuijdgeest D, Khayat R, Ekiert D C, Lee J H, Metlagel Z, Bujny M V, Jongeneelen M, van der Vlugt R, Lamrani M, Korse H J, Geelen E, Sahin O, Sieuwerts M, Brakenhoff J P, Vogels R, Li O T, Poon L L, Peiris M, Koudstaal W, Ward A B, Wilson I A, Goudsmit J, and Friesen R H. 2012. Highly conserved protective epitopes on influenza B viruses. Science, 337:1343-1348.
26. Du L, He Y, Zhou Y, Liu S, Zheng B J, and Jiang S. 2009. The spike protein of SARS-CoV-a target for vaccine and therapeutic development. Nat Rev Microbiol, 7:226-236.
27. Duan J, Yan X, Guo X, Cao W, Han W, Qi C, Feng J, Yang D, Gao G, and Jin G. 2005. A human SARS-CoV neutralizing antibody against epitope on S2 protein. Biochem Biophys Res Commun, 333:186-193.
28. Eaton B T, Broder C C, Middleton D, and Wang L F. 2006. Hendra and Nipah viruses: different and dangerous. Nat Rev Microbiol, 4:23-35.
29. Ekiert D C, Bhabha G, Elsliger M A, Friesen R H, Jongeneelen M, Throsby M, Goudsmit J, and Wilson I A. 2009. Antibody recognition of a highly conserved influenza virus epitope. Science, 324:246-251.
30. Ekiert D C, Friesen R H, Bhabha G, Kwaks T, Jongeneelen M, Yu W, Ophorst C, Cox F, Korse H J, Brandenburg B, Vogels R, Brakenhoff J P, Kompier R, Koldijk M H, Cornelissen L A, Poon L L, Peiris M, Koudstaal W, Wilson I A, and Goudsmit J. 2011. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science, 333:843-850.
31. Elshabrawy H A, Coughlin M M, Baker S C, and Prabhakar B S. 2012. Human Monoclonal Antibodies against Highly Conserved HR1 and HR2 Domains of the SARS-CoV Spike Protein Are More Broadly Neutralizing. PLoS ONE, 7:e50366.
32. Euler Z, and Schuitemaker H. 2012. Cross-reactive broadly neutralizing antibodies: timing is everything. Front Immunol, 3:215.
33. Fennell B J, Darmanin-Sheehan A, Hufton S E, Calabro V, Wu L, Muller M R, Cao W, Gill D, Cunningham O, and Finlay W J. 2010. Dissection of the IgNAR V domain: molecular scanning and orthologue database mining define novel IgNAR hallmarks and affinity maturation mechanisms. J Mol Biol, 400:155-170.
34. Fric J, Bertin-Maghit S, Wang C I, Nardin A, and Waiter L. 2013. Use of human monoclonal antibodies to treat chikungunya virus infection. J Infect Dis, 207:319-322.
35. Friedrich B M, Trefry J C, Biggins J E, Hensley L E, Honko A N, Smith D R, and Olinger G G. 2012. Potential vaccines and post-exposure treatments for filovirus infections. Viruses, 4:1619-1650.
36. Gong R, Chen W, and Dimitrov D S. 2012. Candidate antibody-based therapeutics against HIV-1. BioDrugs, 26:143-162.
37. Gong R, Wang Y, Ying T, and Dimitrov D S. 2012. Bispecific Engineered Antibody Domains (Nanoantibodies) That Interact Noncompetitively with an HIV-1 Neutralizing Epitope and FcRn. PLoS ONE, 7:e42288.
38. Greenough T C, Babcock G J, Roberts A, Hernandez H J, Thomas W D, Jr., Coccia J A, Graziano R F, Srinivasan M, Lowy I, Finberg R W, Subbarao K, Vogel L, Somasundaran M, Luzuriaga K, Sullivan J L, and Ambrosino D M. 2005. Development and characterization of a severe acute respiratory syndrome-associated coronavirusneutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis, 191:507-514.
39. Haynes B F, Kelsoe G, Harrison S C, and Kepler T B. 2012. B-cell-lineage immunogen design in vaccine development with HIV-1 as a case study. Nat Biotechnol, 30:423-433.
40. Higo-Moriguchi K, Akahori Y, Iba Y, Kurosawa Y, and Taniguchi K. 2004. Isolation of human monoclonal antibodies that neutralize human rotavirus. J Virol, 78:3325-3332.
41. Huang C C, Tang M, Zhang M Y, Majeed S, Montabana E, Stanfield R L, Dimitrov D S, Korber B, Sodroski J, Wilson I A, Wyatt R, and Kwong P D. 2005. Structure of a V3-containing HIV-1 gpl20 core. Science, 310:1025-1028.
42. Huang C C, Venturi M, Majeed S, Moore M J, Phogat S, Zhang M Y, Dimitrov D S, Hendrickson W A, Robinson J, Sodroski J, Wyatt R, Choe H, Farzan M, and Kwong P D. 2004. Structural basis of tyrosine sulfation and VH-gene usage in antibodies that recognize the HIV type 1 coreceptor-binding site on gpl20. Proc Natl Acad Sci USA, 101:2706-2711.
43. Hwang W C, Lin Y, Santelli E, Sui J, Jaroszewski L, Stec B, Farzan M, Marasco W A, and Liddington R C. 2006. Structural basis of neutralization by a human anti-severe acute respiratory syndrome spike protein antibody, 80R. J Biol Chem, 281:34610-34616.
44. Jacobs S A, Diem M D, Luo J, Teplyakov A, Obmolova G, Malia T, Gilliland G L, and O'Neil K T. 2012. Design of novel FN3 domains with high stability by a consensus sequence approach. Protein Engineering Design & Selection, 25:107-117.
45. Kajihara M, Marzi A, Nakayama E, Noda T, Kuroda M, Manzoor R, Matsuno K, Feldmann H, Yoshida R, Kawaoka Y, and Takada A. 2012. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J Virol, 86:13467-13474.
46. Kaufmann B, Vogt M R, Goudsmit J, Holdaway H A, Aksyuk A A, Chipman P R, Kuhn R J, Diamond M S, and Rossmann M G 2010. Neutralization of West Nile virus by cross-linking of its surface proteins with Fab fragments of the human monoclonal antibody CR4354. Proc Natl Acad Sci USA, 107:18950-18955.
47. Koide A, Wojcik J, Gilbreth R N, Hoey R J, and Koide S. 2012. Teaching an old scaffold new tricks: monobodies constructed using alternative surfaces of the FN3 scaffold. J Mol Biol, 415:393-405.
48. Kwong P D, and Mascola J R. 2012. Human antibodies that neutralize HIV'-l: identification, structures, and B cell ontogenies. Immunity, 37:412-425.
49. Kwong P D, Wyatt R, Robinson J, Sweet R W, Sodroski J, and Hendrickson W A. 1998. Structure of an HIV gpl20 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature, 393:648-659.
50. Lee J E, Fusco M L, Hessell A J, Oswald W B, Burton D R, and Saphire E O. 2008. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature, 454:177-182.
51. Lee J E, Kuehne A, Abelson D M, Fusco M L, Hart M K, and Saphire E O. 2008. Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain. J Mol Biol, 375:202-216.
52. Li F, Li W, Farzan M, and Harrison S C. 2005. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science, 309:1864-1868.
53. Lindesmith L C, Beltramello M, Donaldson E F, Corti D, Swanstrom J, Debbink K, Lanzavecchia A, and Baric R S. 2012. Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog, 8:e1002705.
54. Marasco W A, and Sui J. 2007. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat Biotechnol, 25:1421-1434.
55. Marzi A, Yoshida R, Miyamoto H, Ishijima M, Suzuki Y, Higuchi M, Matsuyama Y, Igarashi M, Nakayama E, Kuroda M, Saijo M, Feldmann F, Brining D, Feldmann H, and Takada A. 2012. Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of Ebola hemorrhagic fever. PLoS ONE, 7:e36192.
56. Meng X, and Xiang Y. 2012. Generation and characterization of monoclonal antibodies specific for vaccinia virus. Methods Mol Biol, 890:219-232.
57. Meuleman P, Catanese M T, Verhoye L, Desombere I, Farhoudi A, Jones C T, Sheahan T, Grzyb K, Cortese R, Rice C M, Leroux-Roels G, and Nicosia A. 2012. A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo. Hepatology, 55:364-372.
58. Migone T S, Subramanian G M, Zhong J, Healey L M, Corey A, Devalaraja M, Lo L, Ullrich S, Zimmerman J, Chen A, Lewis M, Meister G, Gillum K, Sanford D, Mott J, and Bolmer S D. 2009. Raxibacumab for the treatment of inhalational anthrax. N Engl J Med, 361:135-144.
59. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, Ruker F, and Katinger H. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol, 67:6642-6647.
60. Nakauchi M, Fukushi S, Saijo M, Mizutani T, Ure A E, Romanowski V, Kurane I, and Morikawa S. 2009. Characterization of monoclonal antibodies to Junin virus nucleocapsid protein and application to the diagnosis of hemorrhagic fever caused by South American arenaviruses. Clin Vaccine Immunol, 16:1132-1138.
61. Nybakken G E, Oliphant T, Johnson S, Burke S, Diamond M S, and Fremont D H. 2005. Structural basis of West Nile virus neutralization by a therapeutic antibody. Nature, 437:764-769.
62. Ohta A, Fujita A, Murayama T, Iba Y, Kurosawa Y, Yoshikawa T, and Asano Y. 2009. Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner. Microbes Infect, 11:1029-1036.
63. Oliphant T, Engle M, Nybakken G E, Doane C, Johnson S, Huang L, Gorlatov S, Mehlhop E, Marri A, Chung K M, Ebel G D, Kramer L D, Fremont D H, and Diamond M S. 2005. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med, 11:522-530.
64. Pak J E, Sharon C, Satkunarajah M, Auperin T C, Cameron C M, Kelvin D J, Seetharaman J, Cochrane A, Plummer F A, Berry J D, and Rini J M. 2009. Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain. J Mol Biol, 388:815-823.
65. Prabakaran P, Streaker E, Chen W, and Dimitrov D S. 2011. 454 antibody sequencing-error characterization and correction. BMC Research Notes: In Press.
66. Prabakaran P, Gan J, Wu Y Q, Zhang M Y, Dimitrov D S, and Ji X. 2006. Structural mimicry of CD4 by a cross-reactive HIV-1 neutralizing antibody with CDR-H2 and H3 containing unique motifs. J Mol Biol, 357:82-99.
67. Prabakaran P, Zhu Z, Xiao X, Biragyn A, Dimitrov A S, Broder C C, and Dimitrov D S. 2009. Potent human monoclonal antibodies against SARS CoV, Nipah and Hendra viruses. Expert Opin Biol Ther, 9:355-368.
68. Prabakaran P, Zhu Z, Chen W, Gong R, Feng Y, Streaker E, and Dimitrov D S. 2012. Origin, diversity, and maturation of human antiviral antibodies analyzed by high-throughput sequencing. Front Microbiol, 3:277.
69. Prabakaran P, Gan J, Feng Y, Zhu Z, Choudhry V, Xiao X, Ji X, and Dimitrov D S. 2006. Structure of severe acute respiratory syndrome coronavirus receptor-binding domain complexed with neutralizing antibody. J Biol Chem, 281:15829-15836.
70. Qiu X, Alimonti J B, Melito P L, Fernando L, Stroher U, and Jones S M. 2011. Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol, 141:218-227.
71. Rani M, Bolles M, Donaldson E F, Van Blarcom T, Baric R, Iverson B, and Georgiou G 2012. Increased antibody affinity confers broad in vitro protection against escape mutants of severe acute respiratory syndrome coronavirus. J Virol, 86:9113-9121.
72. Reichert J M. 2008. Monoclonal Antibodies as Innovative Therapeutics. Current Pharmaceutical Biotechnology, 9:423-430.
73. Saijo M, Tang Q, Shimayi B, Han L, Zhang Y, Asiguma M, Tianshu D, Maeda A, Kurane I, and Morikawa S. 2005. Antigen-capture enzyme-linked immunosorbent assay for the diagnosis of crimeancongo hemorrhagic fever using a novel monoclonal antibody. J Med Virol, 77:83-88.
74. Sanchez M D, Pierson T C, McAllister D, Hanna S L, Puffer B A, Valentine L E, Murtadha M M, Hoxie J A, and Doms R W. 2005. Characterization of neutralizing antibodies to West Nile virus. Virology, 336:70-82.
75. Schrama D, Reisfeld R A, and Becker J C. 2006. Antibody targeted drugs as cancer therapeutics. Nature Reviews Drug Discovery, 5:147-159.
76. Scott L J, and Lamb H M. 1999. Palivlzumab. Drugs, 58:305-311; discussion 312-303.
77. Shedlock D J, Bailey M A, Popemack P M, Cunningham J M, Burton D R, and Sullivan N J. 2010. Antibody-mediated neutralization of Ebola virus can occur by two distinct mechanisms. Virology, 401:228-235.
78. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, and Katinger H. 2001. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. Aids Research and Human Retroviruses, 17:1757-1765.
79. Strokappe N, Szynol A, Aasa-Chapman M, Gorlani A, Foreman Quigley A, Hulsik D L, Chen L, Weiss R, de Haard H, and Verrips T. 2012. Llama antibody fragments recognizing various epitopes of the CD4bs neutralize a broad range of HIV-1 subtypes A, B and C. PLoS ONE, 7:e33298.
80. Sui J, Hwang W C, Perez S, Wei G, Aird D, Chen L M, Santelli E, Stec B, Cadwell G, Ali M, Wan H, Murakami A, Yammanuru A, Han T, Cox N J, Bankston L A, Donis R O, Liddington R C, and Marasco W A. 2009. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol, 16:265-273.
81. ter Meulen J, van den Brink E N, Poon L L, Marissen W E, Leung C S, Cox F, Cheung C Y, Bakker A Q, Bogaards J A, van Deventer E, Preiser W, Doerr H W, Chow V T, de Kruif J, Peiris J S, and Goudsmit J. 2006. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. PLoS Med, 3:e237.
82. Throsby M, van den Brink E, Jongeneelen M, Poon L L, Alard P, Cornelissen L, Bakker A, Cox F, van Deventer E, Guan Y, Cinatl J, ter Meulen J, Lasters I, Carsetti R, Peiris M, de Kruif J, and Goudsmit J. 2008. Heterosubtypic neutralizing monoclonal antibodies crossprotective against HSN1 and H1N1 recovered from human IgM+ memory B cells. PLoS ONE, 3:e3942.
83. Traggiai E, Becker S, Subbarao K, Kolesnikova L, Uematsu Y, Gismondo M R, Murphy B R, Rappuoli R, and Lanzavecchia A. 2004. An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nature Medicine, 10:871-875.
84. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore J P, and Katinger H. 1996. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gpl20 glycoprotein of human immunodeficiency virus type 1. J Virol, 70:1100-1108.
85. van Boheemen S, de Graaf M, Lauber C, Bestebroer T M, Raj V S, Zaki A M, Osterhaus A D, Haagmans B L, Gorbalenya A E, Snijder E J, and Fouchier R A. 2012. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. M Bio, 3.
86. van Gils M J, and Sanders R W. 2013. Broadly neutralizing antibodies against HIV-1: templates for a vaccine. Virology, 435:46-56.
87. Verkoczy L, Kelsoe G, Moody M A, and Haynes B F. 2011. Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies. Curr Opin Immunol, 23:383-390.
88. Waldmann T A. 2003. Immunotherapy: past, present and future. Nature Medicine, 9:269-277.
89. Weiner L M, Dhodapkar M V, and Ferrone S. 2009. Monoclonal antibodies for cancer immunotherapy. Lancet, 373:1033-1040.
90. Whittle J R, Zhang R, Khurana S, King L R, Manischewitz J, Golding H, Dormitzer P R, Haynes B F, Walter E B, Moody M A, Kepler T B, Liao H X, and Harrison S C. 2011. Broadly neutralizing human antibody that recognizes the receptor-binding pocket of influenza virus hemagglutinin. Proc Natl Acad Sci U S A, 108:14216-14221.
91. Wilson J A, Hevey M, Bakken R, Guest S, Bray M, Schmaljohn A L, and Hart M K. 2000. Epitopes involved in antibody-mediated protection from Ebola virus. Science, 287:1664-1666.
92. Xiao X, Feng Y, Vu B K, Ishima R, and Dimitrov D S. 2009. A large library based on a novel (CH2) scaffold: identification of HIV-1 inhibitors. Biochem Biophys Res Commun, 387:387-392.
93. Xiao X, Chen W, Feng Y, Zhu Z, Prabakaran P, Wang Y, Zhang M Y, Longo N S, and Dimitrov D S. 2009. Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens. Biochem Biophys Res Commun, 390:404-409.
94. Xiao X D, Chen W Z, Feng Y, and Dimitrov D S. 2009. Maturation Pathways of Cross-Reactive HIV-1 Neutralizing Antibodies. Viruses-Basel, 1:802-817.
95. Xu K, Rajashankar K R, Chan Y P, Himanen J P, Broder C C, and Nikolov D B. 2008. Host cell recognition by the henipaviruses: crystal structures of the Nipah G attachment glycoprotein and its complex with ephrin-B3. Proc Natl Acad Sci USA, 105:9953-9958.
96. Yang Z Y, Werner H C, Kong W P, Leung K, Traggiai E, Lanzavecchia A, and Nabel G J. 2005. Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses. Proc Natl Acad Sci USA, 102:797-801.
97. Ye J Q, Shao H X, and Perez D R. 2012. Passive immune neutralization strategies for prevention and control of influenza A infections. Immunotherapy, 4:175-186.
98. Ying T, Chen W, Gong R, Feng Y, and Dimitrov D S. 2012. Soluble monomeric IgGl Fc. J Biol Chem, 287:19399-19408.
99. Zhang M Y, Choudhry V, Xiao X, and Dimitrov D S. 2005. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. Curr Opin Mol Ther, 7:151-156.
100. Zhang M Y, Xiao X, Sidorov I A, Choudhry V, Cham F, Zhang P F, Bouma P, Zwick M, Choudhary A, Montefiori D C, Broder C C, Burton D R, Quinnan G V, Jr., and Dimitrov D S. 2004. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol, 78:9233-9242.
101. Zhu Z, Bossart K N, Bishop K A, Crameri G, Dimitrov A S, McEachern J A, Feng Y, Middleton D, Wang L F, Broder C C, and Dimitrov D S. 2008. Exceptionally potent cross-reactive neutralization of Nipah and Hendra viruses by a human monoclonal antibody. J Infect Dis, 197:846-853.
102. Zhu Z, Dimitrov A S, Bossart K N, Crameri G, Bishop K A, Choudhry V, Mungall B A, Feng Y R, Choudhary A, Zhang M Y, Feng Y, Wang L F, Xiao X, Eaton B T, Broder C C, and Dimitrov D S. 2006. Potent neutralization of Hendra and Nipah viruses by human monoclonal antibodies. J Virol, 80:891-899.
103. Zhu Z, Chakraborti S, He Y, Roberts A, Sheahan T, Xiao X, Hensley L E, Prabakaran P, Rockx B, Sidorov I A, Corti D, Vogel L, Feng Y, Kim J O, Wang L F, Baric R, Lanzavecchia A, Curtis K M, Nabel G J, Subbarao K, Jiang S, and Dimitrov D S. 2007. Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A, 104:12123-12128.
104. Zhu Z, Qin H R, Chen W, Zhao Q, Shen X, Schutte R, Wang Y, Ofek G, Streaker E, Prabakaran P, Fouda G G, Liao H X, Owens J, Louder M, Yang Y, Klaric K A, Moody M A, Mascola J R, Scott J K, Kwong P D, Montefiori D, Haynes B F, Tomaras G D, and Dimitrov D S. 2011. Cross-reactive HIV-1-neutralizing human monoclonal antibodies identified from a patient with 2F5-like antibodies. J Virol, 85:11401-11408.